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 Chronic kidney disease (CKD) is a common disease exhibiting globally high 
morbidity rate. About 13.3 million people corresponding to 10-13% of general 
population is thought to have CKD in Japan. However, at present, there is no 
effective treatment for end stage CKD except for dialysis and kidney 
transplantation. Recently, the patients requiring dialysis therapy are 
increasing every year, because the treatment that can drastically improve 
quality of life in CKD patients has not been established. CKD ranks in the 
top 3 of the cause of death in dogs and cats, because the application of 
dialysis therapy and kidney transplantation is very limited in veterinary 
medicine. Therefore, the elucidation of pathogenesis in CKD, the 
identification of surrogate markers, the establishment of effective 
treatments for CKD is desired. In this situation, many challenging research 
has been performed to develop renal regeneration therapy. In renal 
development, however, three-dimensional architecture is intricately 
constructed with many types of cells, and many developmental events 
remained unclear. Thus, regeneration technique is delayed in kidney 
compared to other organs. Although CKD is caused by various congenital 
and/or acquired factors, there is a common pathway in which reduced 
number of nephrons causes overload to remaining individual nephron, 
irreversibly deteriorating renal damage (Brenner’s theory). Progressively 
reduced number of nephrons result in reduced excretive function, renal 
anemia, and renal fibrosis at end stage of kidney disease. On the other hand, 
total number of nephrons has been reported to vary in humans and to be 
closely associated with birth weight. A congenitally reduced number of 
nephrons is considered an important risk factor related with pathogenesis 
and prognosis of CKD. Therefore elucidating mechanism for determining 
nephron number during renal development will provide important 
information useful for developing kidney regeneration therapy and 
estimating a risk factor for CKD. In addition, elucidating mechanism by 
which congenitally reduced number of nephrons causes CKD might provide 
clues to understand pathological process common in different types of CKD 
by caused by various factors. In this thesis, I revealed the cause of reduced 
nephron number during embryonic development and the pathological 
progression of CKD in hypoplastic kidney (HPK) rats with congenitally 
reduced (-80%) number of nephrons resulting from loss-of-function type 
mutation of Astrin gene which is known to be related with the progression of 
mitotic metaphase and with the inhibition of hyperactivation of mTOR 
signaling. Finally, I discussed about possible therapeutic strategies and 
molecularly targets based on the results obtained in this study. 
  In chapter 2, I demonstrated that HPK rats show macrocytic erythropeina 
with the progression of CKD. In general, major source of erythropoietin 
(EPO) is considered fibroblasts located in juxtamedullary interstitium. EPO 
is secreted from fibroblasts in response to hypoxia and can induce 
erythropoiesis in bone marrow. Normocytic normochromic anemia 
accompanied by reduced response of EPO production to hypoxia is often 
observed in end stage of CKD. Recently, this pathological condition is 
considered to be caused by the transdifferentiation of EPO-producing 
fibroblasts into myofibroblasts with the progression of interstitial fibrosis. I 
found that HPK rats have normal level of plasma EPO concentrations under 
normoxic condition in despite of the appearance of CKD symptoms. 
Interestingly, EPO mRNA expression was decreased in kidney and increased 
in liver of HPK rats, indicating that increased hepatic EPO production might 
compensate decreased renal EPO production. Moreover, EPO mRNA 
expression were normally induced by hypoxic condition in both kidney and 
liver of KPK rats at 140 days of age, indicating HPK already affected by 
fibrosis still has potential to produce EPO in response to hypoxia. On the 
other hand, we found increased the fragility of erythrocyte membrane, the 
promotion of splenic hemosiderosis, and decreased serum transferrin 
concentration, normal level of plasma ion due to significantly increased 
transferrin saturation in HPK. These results suggested that, although 
erythropoiesis in HPK is maintained almost normal by hepatic compensative 
EPO production against renal reduced production, erythropenia is induced 
by hemolysis of red blood cells. 
 In chapter 3, I demonstrated that glomerular lesions are prior to interstitial 
alterations in renal fibrosis of HPK with 80% nephron reduction. Although it 
is known that a considerably reduced number of nephrons progressively 
induces renal damage via overload to individual nephron, it is still unknown 
how many nephrons are required for maintenance of normal renal function 
through life span. We found glomerular hypertrophy, discontinuous 
immunostaining of podocin along the glomerular basal membrane, and 
infiltration of inflammatory macrophages into glomerulus in HPK at 35 and 
70 days of age. At 70 days of age and afterwards, accumulation of 
extracellular matrixes (ECMs), increase in mesangial cells, and glomerular 
sclerosis were gradually deteriorated in HPK. In accordance with these 
changes, glomerular PDGF- and TGF-ß-positive areas were increased in 
HPK. Glomerular PDGFr-ß-positive area was significantly increased in HPK, 
whereas α-SMA-positive myofibroblasts were rarely detected in glomerular 
tufts in spite of the appearance of myofibroblasts in glomerular parietal 
epithelium along Bowman’s capsular walls of HPK. On the other hand, in 
interstitial tissue, age-related increase in accumulation of ECMs was 
accompanied by the age-related increase of myofibroblats by 
transdifferentiation from increased fibroblasts in the intrestitium of HPK 
after the progression of glomerular injury. In accordance with these 
alterations, we detected infiltration of macrophages into interstitium at 140 
and 210 days of age. PDGF-positive area was also increased in 
tubulointrestitium with fibrosis. These results indicated that congenital 80% 
nephron reduction results in progressive CKD resulting in renal fibrosis. In 
HPK, moreover, glomerular lesions appeared early but progressed slowly 
without increased myofibroblasts, whereas interstitial fibrosis appeared 
later but progressed rapidly with increased myofibroblasts. These 
pathological changes might be mediated by growth factors including PDGF 
and TGF-β.  
 In chapter 4, I demonstrated that loss of functional Astrin causes nephron 
reduction via decreased branching of ureteric bud (UB) associated with 
increased apoptosis of metanephric mesenchyme (MM). Normal renal 
development progresses through interaction between UB and MM. UB is the 
first branch of Wolffian duct as a primordium of collecting duct, advances 
into MM, and interacts with MM surrounding UB. In HPK metanephros, 
increased apoptosis and decreased proliferation were observed in MM cell 
surrounding UB. In addition, population of MM cells expressing upstream 
interaction signals (Sall1 and Pax2) and mRNA expression of Sall1, Kif26b, 
and Pax2 were already decreased in HPK metanephros at embryonic day (E) 
14.5, whereas decrease in mRNA expression of other interaction signals was 
not detected. In normal metanephric development, MM cells form 
Six2-positive cap cluster surrounding UB tips. I found decrease in 
metanephric size, thinning of Six2-positive cap cluster, and decrease in Six2 
positive cap area around individual UB in HPK metanephros at E14.5, 
whereas reduced branching of UB was initially detected at E15.5 in HPK. 
Therefore, it was suggested that MM is mainly affected by loss of Astrin, 
secondarily causing reduced branching of UB. MM clusters are believed to 
differentiate into most of nephron components, and tubular epithelia and 
podocytes are differentiated through mesenchymal-epitherial-transition 
(MET). I observed normal progression of MET in HPK metanephros. It has 
been reported that the knockdown of Astrin in HeLa cells causes mitotic 
arrest at metaphase in cell cycle, resulting in apoptosis. In accordance with 
the phenotype in HeLa cells, abnormal mitotic metaphase and subsequent 
apoptotic cell death were observed in immature Sertoli cells of testicular 
dysplasia accompanied in male HPK rats. Therefore I assumed that decrease 
in MM of HPK metanephros would be caused by loss of Astrin function 
associated with cell cycle progression. Unexpectedly, increase of metaphase 
cells positive for phosphor-histion H3 was not detected in HPK metanephros 
at all embryonic days examined. Alternatively, as another function of Astrin, 
it has been reported that Astrin inhibits apoptosis through suppressing 
hyperactivation of mTOR signaling via recruiting Raptor, a component of 
mTOR complex 1, into stress granules in HeLa cells under stress condition. 
In my experiments regarding to mTOR signaling, increased mRNA 
expression of mTOR and it’s downstream S6K1 and increased 
phosphorylation of S6K1 were detected in HPK metanephros, suggesting 
that Astrin is associated with the regulation of mTOR signaling in 
developing metanephros. 
 In chapter 5, I tried to replicate metanephric phenotype using in vitro organ 
culture method and analyzed the phenotype of MM cells affected by Astrin 
deficient. The growth of E14.5 HPK metanephros cultured for 3 days was 
apparently delayed compared to that in normal metanephros. When 
metanephros were cultured with low dose (0.05ng/ml) of mTOR inhibitor 
(Evelorimus), metanephros derived from normal embryos were significantly 
decreased in size compared to vehicle control (DMSO), whereas metanephros 
from HPK embryos were almost comparable in size to control. In addition, 
the increment of metanephric size for 3 days culture was significantly lower 
in HPK than in normal in vehicle controls, whereas HPK metanephros 
exhibited significantly larger increment compared to normal in Evelorimus 
treatment. These results suggested that the regulation of mTOR signaling 
with Astrin is related with metanephric phenotype of HPK. Furthermore, 
Six2-positive MM cells were markedly decreased in HPK metanephros 
cultured for 3 days, indicating early loss of MM cells. In order to analyze the 
affect of Astrin defect in MM cells, I established culture system of isolated 
MM cells from E14.5 metanephros in individual rat embryo. 
Primary-cultured MM cells derived from normal metanephros expressed 
mesenchymal markers and Astrin but not epithelial and stromal markers. 
Passage 1 (P1)-MM cells derived from HPK metanephros showed decreased 
expression of mesenchymal markers and increased expression of a stromal 
marker. RT-PCR fragment including insertion mutation of Astrin transcript 
was hardly detected in HPK P1-MM cells. These results indicated altered 
stemness in HPK MM cells losing Astrin function. Furthermore, I observed 
increased apoptosis in Six2-positive HPK P1-MM cells, suggesting cultured 
HPK MM cells replicate similar phenotype as shown in vivo. Although both 
normal and HPK P1-MM cells formed immature podoplanin-positive clusters 
through induction with embryonic spinal cord, clusters in HPK MM cells 
look like immature and small compared to normal MM cells, suggesting it 
need more time to form glomerulus in HPK compared to normal. 
 In summary, the present study suggested that the loss of Astrin changes 
stemness in MM cells and decreases signals related with interaction between 
MM and UB. It is also suggested that increased apoptosis and decreased 
proliferation in MM cells induce reduced branching of UB with thinning of 
nephron formation layer and early reduction of stem cells. These sequential 
events might finally lead to 80% nephron reduction. Interestingly my 
experiments also suggested that these defective processes are involved in 
hyperactivation of mTOR signaling under the loss of Astrin. In HPK rats, 
resulting 80% nephron reduction causes CKD at adult and leads to renal 
fibrosis at advanced age. The progression of CKD in HPK rats is 
characterized by early and slow progression of glomerular sclerosis, later 
appearance and rapid progression of interstitial fibrosis, and specifically 
macrocytic erythropenia. In last chapter, I described my collaborating 
research demonstrating that low dose of Everolimus treatment for long 
period attenuates renal dysfunction and fibrosis in HPK rats. These drastic 
effects might be mediated by preventing PDGF signaling by mTOR 
inhibition. Taken together, through a series of my studies, it was indicated 
that activation of mTOR signaling is associated with not only fibrosis via 
increased myofibroblasts but also early reduction of mesenchyme 
nephrogenic progenitors. I hope in future these evidences will contribute to 
reveal congenital risk for CKD, to improve renal regeneration therapies, and 
to develop molecularly targeted drag therapies against renal fibrosis. 
